Pfizer, Inc. is working on expanding the Sayana® Press in South Asia and Africa, a new form of the injectable Depo-Provera contraceptive. Partnering with USAID, the Bill & Melinda Gates Foundation, DFID, UNFPA, and PATH, over 12 million doses of Depo-Provera will be distributed. Depo-Provera protects women for up to three months. Injectables are highly desired as a method of contraceptive due to their discretion. The Sayana Press uses the Uniject™ injection system to deliver a single dose of depot medroxyprogesterone acetate (DMPA) subcutaneously.
Sayana Press is approved in the EU and in several countries around the world, and is not currently labeled for self injection. The program to increase access to Sayana Press will continue through 2016.